Skip to content

Outcomes 8 Years After Minimal Invasive THA

Patient-relevant Outcomes 8 Years After Minimally Invasive Total Hip Replacement - a Randomized Prospective Study

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03657953
Enrollment
157
Registered
2018-09-05
Start date
2006-01-01
Completion date
2015-09-30
Last updated
2018-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis, Hip

Keywords

Total Hip Arthroplasty, minimally invasive, Patient-relevant outcomes

Brief summary

There exists only limited scientific evidence concerning medium- to long-term benefits concerning minimally invasive (MI) total hip arthroplasty (THA). The investigators examined in a randomized study design 157 patients 8 years after THA, which were performed via 3 different surgical approaches.

Detailed description

In contrast to reported short-term advantages of minimally invasive (MI) total hip arthroplasty (THA) there exists only limited scientific evidence concerning medium- to long-term benefits. The investigators therefore sought to answer the following questions: Is the functional medium-term outcome in THA patients with MI-anterior(MI-A) and MI-anterolateral (MI-AL) approach superior to those treated by direct lateral approach (DLA)? Is the level of life quality increased by MI-THA? Is patient satisfaction higher by MI-THA? Is the revision rate reduced by MI-THA?

Interventions

Sponsors

Stryker Instruments
CollaboratorINDUSTRY
Technische Universität Dresden
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Intervention model description

single-center prospective randomized study design

Eligibility

Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No

Inclusion criteria

* clinical and radiologic signs of advanced hip joint Degeneration * Patients from age 18 to 75

Exclusion criteria

* osteoporosis and * osteomalacia, * preceding surgery or radiation therapy in the proximity of the affected hip joint, * progressive neoplasia, * preceding or manifest infection of the affected joint and its surrounding soft tissues, * rheumatoid arthritis, * hip dysplasia Hartofilakidis type 2 or 3, * non-compliance, * chronic neurological or psychiatric diseases, * ongoing pregnancy

Design outcomes

Primary

MeasureTime frameDescription
Physical function hip - Harris-Hip-Score (HHS)change from baseline (preoperative) at 8 years after THAHarris-Hip-Score (worst=0, best=100)

Secondary

MeasureTime frameDescription
Satisfaction Levelat 8 years after THASatisfaction scale (worst=0, best=10)
health related Quality of life - Indexchange from baseline (preoperative) at 8 years after THAEuroQol in 5 dimensions (EQ-5D) Index (worst=0, best=1)
health related Quality of life - VASchange from baseline (preoperative) at 8 years after THAEQ-Visual Analogue Scale (worst=0, best=100)
Physical function hip - WOMACchange from baseline (preoperative) at 8 years after THAWOMAC Total Score (worst=0, best=100)
Revision rateat 8 years after THARevision rate using Kaplan-Meier-Survival Analysis
Physical Activity Performance Test: walkingchange from baseline (preoperative) at 8 years after THA25-meter walking time
Physical Activity Performance Test: stair climbingchange from baseline (preoperative) at 8 years after THA5-step walking time
Physical Activitychange from baseline (preoperative) at 8 years after THAUniversity of California, Los Angeles (UCLA) Activity Scale (worst=1, best=10)

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026